In the depths of the internet, wild speculation and claims are rife. When the scuttlebutt relates to public companies it can be tough for investors to hold their nerve.

But one post that recently popped up on Cafepharma – a forum for pharmaceutical sales representatives – may make even the most resilient Acrux investor tremble.